title: [Biological treatments in pediatric IBD].
abstract: Biological treatments in pediatric IBD In Sweden, there are an estimated 1 500 pediatric IBD patients. We sent out a survey regarding the use of biological treatments in pediatric IBD to pediatric gastroenterologists in Sweden. Of 1 098 recorded IBD patients, 17% had ongoing treatment with biological drugs. The drugs used were almost exclusively infliximab and adalimumab, i.e. anti-TNF-alpha. Use of biologics varied among responders. Anaphylactic reactions and other types of infusion reactions were the most frequent side effects.
authors.affiliation: Barn- och ungdomskliniken - Örebro, Sweden Barn- och ungdomskliniken - Orebro, Sweden.
authors.forename: Magnus
authors.initials: M
authors.lastname: Svensson
authors.affiliation: Barn- och ungdomskliniken - Örebro, Sweden Barn- och ungdomskliniken - Orebro, Sweden.
authors.forename: Eva
authors.initials: E
authors.lastname: Lindberg
authors.affiliation: - Stockholm, Sweden - Stockholm, Sweden.
authors.forename: Jonas F
authors.initials: JF
authors.lastname: Ludvigsson
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy / Q000009:adverse effects / Q000706:statistics & numerical data*; D002648:Child; D000072102:Gastroenterologists; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000453:epidemiology; D011795:Surveys and Questionnaires; D013548:Sweden / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha